SillaJen Pays $150M For Tumor Treatment Firm
South Korea-based biotherapeutics and contract research company SillaJen Inc. will acquire San Francisco clinical-stage biotechnology firm Jennerex Inc. for about $150 million, SillaJen said Tuesday, in a merger that would bring...To view the full article, register now.
Already a subscriber? Click here to view full article